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a-Synuclein is genetically and
neuropathologically linked to Parkinson’s
disease. However, the mechanisms of
known genetic toxicity modulators in a
yeast model system remain largely
unknown. In order to identify cellular
rescue pathways at high-throughput, we
have paired mass spectrometry-based
monitoring of pathway activity and
growth profiles through regression
analysis. The results predicted a critical
role for the protein Pah1 in lipid
metabolism. Indeed, specific
perturbation of Pah1 activity determines
inclusion formation and toxicity thereby
suggesting a potential target for
combating pathologies associated with
a-Synuclein accumulation.Inc.
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Proteinaceous inclusions containing alpha-synuclein
(a-Syn) have been implicated in neuronal toxicity in
Parkinson’s disease, but the pathways that modulate
toxicity remain enigmatic. Here, we used a targeted
proteomic assay to simultaneously measure 269
pathway activation markers and proteins deregulated
by a-Syn expression across a panel of 33 Saccharo-
myces cerevisiae strains that genetically modulate
a-Syn toxicity. Applying multidimensional linear
regression analysis to these data predicted Pah1, a
phosphatase that catalyzes conversion of phospha-
tidic acid to diacylglycerol at the endoplasmic
reticulum membrane, as an effector of rescue.
Follow-up studies demonstrated that inhibition of
Pah1 activity ameliorates the toxic effects of a-Syn,
indicate that the diacylglycerol branch of lipid meta-
bolism could enhance a-Syn neuronal cytotoxicity,
and suggest a link between a-Syn toxicity and the
biology of lipid droplets.
INTRODUCTION
Alpha-synuclein (a-Syn) is an aggregation-prone protein impli-
cated in Parkinson’s disease (PD). Insoluble a-Syn species are
a major component of Lewy bodies, which are proteinaceous in-
clusions found in post-mortem analyses of PD patient brains
(Spillantini et al., 1997). Amplification and mutations in the
gene encoding a-Syn result in dominant familial parkinsonism
(Polymeropoulos et al., 1997; Singleton et al., 2003). a-Syn is a
soluble, cytoplasmic protein that can bind to certain lipids andCell Systems 9, 309–320, Septe
This is an open access article under the CC BY-Ncellular membranes (Snead and Eliezer, 2014). These interac-
tions appear to be important for the normal function of a-Syn
and may also play roles in the aggregation of the protein into
cytoplasmic inclusions, but the precise molecular events under-
lying a-Syn neuronal toxicity remain elusive.
The proteotoxicity of a-Syn has been modeled in a variety of
systems (Fares et al., 2016; Khurana and Lindquist, 2010; Luk
et al., 2012), including Saccharomyces cerevisiae (Outeiro and
Lindquist, 2003), resulting in translatable findings (Chung et al.,
2013; Tardiff et al., 2013). In yeast, ectopically expressed
a-Syn forms intracellular inclusions and causes dose- and
time-dependent cytotoxicity (Outeiro and Lindquist, 2003).
Genome-wide screens performed in yeast have identified
dozens of genes that upon overexpression or silencing modu-
late toxicity (Cooper et al., 2006; Gitler et al., 2009; Khurana et
al., 2017; Willingham et al., 2003; Yeger-Lotem et al., 2009).
The human homologues of several conserved yeast genes
from this set, such as RAB1 and NEDD4 (Chung et al., 2013;
Cooper et al., 2006), modulate a-Syn toxicity in neuronal cells,
and mutations in another identified gene ATP13A2 (also known
as PARK9) cause an autosomal recessive form of PD (Gitler
et al., 2009; Ramirez et al., 2006). Despite these promising
findings and the agreement across species, the molecular
mechanisms of genetic modifiers of a-Syn toxicity are largely
unknown.
In this study, we sought to systematically identify pathways
and biological processes that act downstream of genetic modi-
fiers of a-Syn toxicity. We used a recently developed proteomics
approach that enables simultaneous monitoring of activation
states of a variety of biological processes (Soste et al., 2014).
This approach is based on quantitative detection of sentinel pro-
teins, which are biological markers that change in abundance or
phosphorylation state or are cleaved at specific sites in response
to changes in activity of the associated pathway. Examples of
sentinels are levels of Atg8 or cleavage of Ape1, which arember 25, 2019 ª 2019 The Authors. Published by Elsevier Inc. 309
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. RelatingGrowth and PathwayActivationData throughRegressionAnalysis to Identify Effectors of Rescue from a-Syn-Induced Toxicity
(A) Workflow to predict cellular pathways that rescue yeast from a-Syn-induced toxicity. Mod, a-Syn genetic modulator.
(B) Sentinel quantification for each a-Syn genetic modulator. Genetic modulators are ordered in columns according to their genetic modulation effect from
enhancement of toxicity (blue) to suppression of toxicity (red). aSyn, a-Syn expression without genetic modulation. Phosphopeptide (dark purple) and protein
(legend continued on next page)
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indicators of activation of autophagy (Klionsky, 2007; Suzuki
et al., 2002), and phosphorylation of MAP kinases that mark acti-
vation of this pathway (Cherkasova, 2006).
As sentinels of a-Syn-mediated toxicity, we monitored 269
total markers: 178 sentinels report the activation states of 140
biological processes and 91 sentinels that were selected from
shotgun proteomic analyses of a-Syn-perturbed yeast or prior
knowledge about a-Syn biology. We analyzed genetically engi-
neered strains that simultaneously express a-Syn and one of
33 different a-Syn genetic modulators. In order to identify
pathways that rescue cells from a-Syn-mediated toxicity, we
employed a multiple linear regression approach, which impli-
cated Pah1, a phosphatase that catalyzes conversion of phos-
phatidic acid to diacylglycerol at the endoplasmic reticulum
(ER), as an effector of rescue. Thus, a lipid biosynthetic pathway
is a potential instrument for amelioration of a-Syn-induced
pathology.
RESULTS
Proteome Responses to a-Syn Toxicity in Yeast
a-Syn pathobiology can be modeled in yeast by inducible
expression of human a-Syn (Outeiro and Lindquist, 2003).
Expression of a single a-Syn copy results in its localization to
the plasma membrane with no appreciable toxicity, whereas
expression of two copies leads to the formation of large cyto-
plasmic inclusions and inhibition of yeast growth. We performed
shotgun proteomics and phosphoproteomics analyses at 6 h
post-induction of expression of two copies of a-Syn and of
vector control. a-Syn intracellular inclusions were detected in
the a-Syn-expressing cells and while growth rate was reduced
compared to control cells, a-Syn-expressing cells remained
viable (Figures S1A–S1C). In total, 3,679 proteins and 5,464
phosphopeptides were quantified using a label-free proteomics
approach. Levels of 160 proteins and 228 phosphopeptides
were significantly different in a-Syn-expressing cells compared
to control (fold change R 2, q % 0.01, Figures S1D–S1G;
Table S1).
Functional enrichment analyses of regulated proteins and
phosphoproteins based on gene ontology (GO) terms and
Munich Information Center For Protein Sequences (MIPS) cat-
egories revealed differential expression of AGC protein kinase-
encoding genes and genes involved in the vacuole, the ER,
and the plasma membrane (Table S2), three subcellular loca-
tions known to be affected by a-Syn (Gitler et al., 2009; Petroi
et al., 2012). Next, we asked whether proteins upregulated in
a-Syn-expressing cells were toxic when expressed beyond a(light purple) pathway sentinels are hierarchically clustered in rows. Log2 fold-chan
of green (decreased) to red (increased). Gray bar denotes cluster of oppositely r
(C) Regression analysis of pathway sentinels and genetic rescue using stability se
( bP) plotted as a function of the regularization parameter (l) displays stability paths
selection probability (horizontal red line, 0.6) after fitting a multiple linear regressio
blue paths indicate a negative association. Corresponding selected pathway sen
(D) Correlation plots for two sentinel proteins, Adi1 and Pah1. Plots show the
respective cellular process, heat-shock response and lipid metabolism, as monito
sites S744 and S748 relative to the vector strain. r, Pearson correlation coefficie
(E) Schematic of the role of Pah1 in lipid metabolism. Pah1 is dephosphory
P, Phosphorylation.certain level by cross-referencing a previously reported dataset
(Makanae et al., 2013). Four significantly upregulated proteins
(Erg2, Erg25, Nce102, and Vma3) are encoded by dosage-
sensitive genes, suggesting that a-Syn toxicity could be linked
to increased expression of these genes. Of 102 proteins previ-
ously shown to be associated with rescue from a-Syn toxicity
(Khurana et al., 2017; Yeger-Lotem et al., 2009), 62 were iden-
tified in our screen, and three of these (Cmc2, Pan2, and Osh2)
were significantly upregulated (Table S1, red). Upregulation of
these genes could counteract toxicity of a-Syn (Cooper et al.,
2006; Gitler et al., 2009).
Identification of Pathways that Rescue from a-Syn
Toxicity Using an Expanded Sentinel Assay
The sentinel assay previously developed by our group quantified
202 (phospho)proteins that report known pathway activation
events in response to well-characterized perturbations (Soste
et al., 2014).We reasoned thatmonitoring the extent of activation
of these pathways in response to expression of genetic modula-
tors of a-Syn toxicity would provide a comprehensive view of
their cellular effects. As a-Syn may trigger molecular events
not captured by our original assay, we expanded it to include
33 proteins and 66 phosphopeptides that either reacted to the
overexpression of a-Syn and were prioritized based on ampli-
tude of response, known functions, and conservation in humans
or were previously linked to a-Syn. In the latter set, we included
sentinels for a phosphorylation site and three ubiquitination sites
on a-Syn since these modifications were implicated in toxicity
(Oueslati et al., 2010, 2012) and a marker for the degradation
of Cpy1, which has been used as a reporter for an a-Syn-induced
vesicle trafficking defect (Cooper et al., 2006). We developed
targeted quantitative proteomics assays based on parallel
reaction monitoring (PRM) mass spectrometry for these proteins
(Tables S3 and S4).
The expanded sentinel assaywas used to analyze effects of 33
genetic modulators of a-Syn identified through previous screens
and hypothesis-driven studies (Cooper et al., 2006; Gitler et al.,
2009; Khurana et al., 2017; Tardiff et al., 2013; Yeger-Lotem et
al., 2009) (Figure 1A; Table S5). We expressed each genetic
modulator together with a-Syn, both under control of a galac-
tose-inducible promoter. After 6 h, we monitored pathway
activation. We also quantified the extent of rescue or toxicity
enhancement achieved by expression of each geneticmodulator
compared to cells that did not express the modulator by quanti-
tative analyses of growth curves.
We quantified a total of 269 sentinels per genetic modulator
(Figure 1B; Table S6). This consisted of 178 generic pathwayge (FC) in sentinel abundance relative to vector strain is shown on a color scale
egulated sentinels. See also Tables S6, S7, and S8.
lection in order to identify strongest predictors of rescue. Selection probability
of phosphopeptides (left) and proteins (right). Sentinels that passed the cutoff of
n model are colored: red paths indicate a positive association with rescue, and
tinels are shown in Table S12.
extent of rescue relative to the unmodulated a-Syn strain and report on the
red by FC of an Adi1 peptide and the Pah1 peptide containing phosphorylation
nt. p, p-value from application of the correlation test (n = 37).
lated by the Nem1-Spo7 complex to catalyze conversion of PA into DAG.
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Figure 2. Network Paths Connecting a-Syn Genetic Modulators to Known Regulators of Pah1
(A) A subgraph of nodes included in the shortest paths between a-Syn genetic modulators and their closest target among known Pah1 regulators (Nem1-Spo7,
Cdc28, PKA complex, casein kinase II complex, Pho80-85, Pkc1) was obtained using the STRING Saccharomyces cerevisiae network. Genetic modulators are
(legend continued on next page)
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markers (140 biological processes) and 91 a-Syn-specific
markers, made up of 103 phosphopeptides and 166 proteins.
In 88% of cases, expression of genes expected to ameliorate
a-Syn-mediated toxicity or to increase toxicity matched findings
from previous genetic screens (Figure S1H; Table S7). Clustering
based on the similarities of sentinel profiles, revealed that mod-
ulators involved in the same cellular process generally grouped
together (Figure S1I) and that modulators from related processes
(e.g., endocytosis and vesicle transport) clustered in proximity.
Thus, closely related modulators induce similar downstream ef-
fects. The mean Pearson correlation coefficient (r) and the coef-
ficient of determination (R2) for sentinel abundances from repli-
cated analysis of unmodulated a-Syn strains were 0.92 and
0.85 for proteins and 0.78 and 0.61 for phosphopeptides,
respectively (Figure S1J). We also identified 100 proteins that
were oppositely regulated upon expression of genetic enhancers
versus genetic suppressors of toxicity (Figure 1B, gray bar,
Table S8) that were enriched for processes previously attributed
to a-Syn toxicity such as oxidative stress and protein folding
(Table S9).
Next, we identified pathways that best correlated with the
extent of rescue based on the abundances of the respective
sentinels. Rather than individually correlating the state of each
sentinel with rescue of the yeast strain, we used a regularized
multiple regression approach that accounted for the fact that
multiple pathways together might best explain the phenotypic
rescue. We applied sparse linear regression analyses based on
lasso with stability selection (Meinshausen and B€uhlmann,
2010) (see STAR Methods, Figure 1C; Tables S10 and S11).
For the majority of proteins and pathways we found no correla-
tion between the extent of rescue and abundance of the associ-
ated sentinel (Figure 1D; left, Figures S2A and S2B). Correlations
were observed for some sentinels (Figure S2C); however, only
four phosphoprotein sentinels (Pah1, Num1, She3, and Osh1)
and seven protein sentinels (Met10, Ncp1, Car1, Dot5, Gpp1,
Ero1, and Cwp1) were predictive of rescue with a selection
probability greater than or equal to 60% (Figure 1C, red and
blue, Figure S2D; Table S12). Thesemarkers are involved in lipid,
sterol, and amino acid metabolism, mitochondria-ER-cortex-
anchoring, cell-wall biosynthesis, mRNA transport, cortical ER
inheritance, oxidative stress, and protein folding. Biological pro-
cesses associated with sentinels that correlated with rescue
included vesicle-trafficking defects, which were previously
shown to be involved in a-Syn toxicity (Cooper et al., 2006).
Vesicle trafficking wasmonitored in our assay by the ER-to-Golgi
trafficking of the protein Cpy1, which had a selection frequency
below 60% but ranked 12th of 166 protein sentinels (Table S11).
This indicates that our method captured meaningful biological
events associated with a-Syn toxicity.
The top ranked pathway sentinel was phosphorylation of the
protein Pah1, a marker for the biosynthesis of diacylglycerol
(DAG) (Figure 1D, right, Figure S2D; Table S12). Dephosphoryla-
tion of Pah1 by the Nem1-Spo7 complex is known to activate the
enzyme (O’Hara et al., 2006; Su et al., 2014). Activated Pah1colored by a blue to red gradient according to their rescue effect; known Pah1 reg
The known Pah1 regulators are 14 proteins involved in six complexes; complex
(B) The closest Pah1 regulator of each modulator is shown (black cell). If more tha
then multiple Pah1 regulators were designated as closest. See also Table S13.catalyzes the conversion of phosphatidic acid (PA) to DAG at
the ER membrane; inactive Pah1 is localized to the cytosol
(Hsieh et al., 2016) (Figure 1E). Our data indicate that phosphor-
ylation, and therefore inactivation, of Pah1 positively correlates
with rescue from a-Syn toxicity and suggests that Pah1 may
act downstream of a broad range of a-Syn genetic modulators.
Network Paths Linking Genetic Modulators to Pah1
Overexpression of several genetic modulators of a-Syn toxicity
resulted in the regulation of Pah1 phosphorylation. To assess
how diverse genetic modulators are linked to Pah1 phosphoryla-
tion, we performed network analyses using the tool, STRING
(Szklarczyk et al., 2019). We searched in the high-confidence
STRING yeast protein association network for the shortest paths
between each genetic modulator and six known upstream regu-
lators of Pah1 (Nem1-Spo7, Cdc28, PKA complex, CK2 com-
plex, Pho80-Pho85, and Pkc1) (Figure 2A). In the resulting sub-
network, 25 genetic modulators were linked to Pah1 regulators
whereas eight were not. Shortest path analysis revealed com-
mon and disparate downstream paths connecting modulators
and Pah1. Modulators known to be involved in the same biolog-
ical process grouped together in the Pah1 network. Modulators
that induced the largest fold changes in Pah1 phosphorylation
were direct neighbors or within two edges of a known Pah1 regu-
lator (Figure S2E). For example, the modulators TIF4631,
TIF4632, and YKT6 are within two edges of the known regulator
Pkc1, which phosphorylates Pah1 to stimulate its proteasomal
degradation (Hsieh et al., 2015). Modulators PDE2 and HRD1
are within two edges of the PKA complex, which has the oppo-
site effect on Pah1 proteasomal degradation and attenuates its
catalytic activity (Su et al., 2012). YPT1 and CDC5 are within
two edges of Cdc28, which has not been found to affect Pah1
catalytic activity but does phosphorylate Pah1 and potentially in-
fluences its localization (Hsieh et al., 2016). For some modula-
tors, more than one Pah1 phosphorylation regulator was equally
close (i.e., there were multiple paths of the same length) (Fig-
ure 2B; Table S13). 40% of modulators were closest to a single
Pah1 regulator, 36% were equidistant to two regulators, and
24% were equidistant to three or four. The most central nodes
in the network were Cdc28, Ubi4, Ura2, Tpk1, and Pkc1
(Table S13).
Deletion of NEM1 Increases Levels of Phosphorylated
Pah1 and Suppresses a-Syn Toxicity
We next assessed whether Pah1 phosphorylation is sufficient to
ameliorate a-Syn-mediated toxicity. First, we deleted the gene
encoding the phosphatase Nem1, which is responsible for
dephosphorylation of Pah1 at the two residues identified in our
screen and five other residues (Santos-Rosa et al., 2005). The
a-Syn-expressing Dnem1 strain grew better than the a-Syn-ex-
pressing strain without the deletion, suggesting that phosphory-
lation of Pah1 promotes cellular fitness in the presence of high
levels of a-Syn (Figure 3A). To confirm that phosphorylation of
Pah1 was indeed increased in the a-Syn-expressing Dnem1ulators are colored rings and discovered intermediate nodes are shown in gray.
members have matched colors.
n one Pah1 regulator had the same shortest distance from a genetic modulator,
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Figure 3. Deletion of NEM1 Suppresses
Toxicity Caused by a-Syn Expression and
Alters Inclusion Phenotype
(A) Cultures of indicated yeast strains spotted by
serial dilution onto glucose and galactose-contain-
ing medium. a-Syn expression is under the control
of a galactose-inducible promoter.
(B) Pah1 phosphorylation levels assessed by tar-
geted proteomic measurement of two phospho-
peptides containing three known Nem1-target sites
and two phosphopeptides with two residues not
targeted by Nem1. See also Table S14. Mean ±
standard deviation abundances for two peptides in
each group (Nem1 target residues and other resi-
dues) in biological triplicates were compared
(two-way ANOVA adjusted for multiple compari-
sons, n = 6, alpha = 0.05).
(C) Representative images of cells that express
a-Syn-YFP and mutants with opposite effects on
Pah1 phosphorylation status. Scale bars represent
10 mm. See also Figure S3E.
(D) Cells with and without a-Syn-YFP inclusions
were counted in three fields of view. The mean
counts expressed as percentages ± standard
deviation of biological replicates were compared
(one-way ANOVA adjusted for multiple compari-
sons, n > 3, alpha = 0.05). ****, p < 0.0001.strain, we measured phosphorylation of Pah1 by targeted mass
spectrometry. As expected, Pah1 phosphorylation at known
Nem1 target sites, and not at other residues, was significantly
increased in the absence of the Nem1 phosphatase (Figure 3B).
Of note, no Dnem1-induced suppression of toxicity was
observed in cells expressing aggregation-prone proteins TDP-
43 and FUS, indicating that the effect is specific to a-Syn
(Figure S3A). Western blot analyses showed that mutants that
resulted in Pah1-related rescue or enhanced toxicity did not
affect a-Syn expression (Figure S3B). Collectively, these data
confirm the prediction resulting from our sentinel analysis that
Pah1 phosphorylation specifically counteracts the toxic effects
of a-Syn.
The Diacylglycerol Branch of Lipid Metabolism
Enhances a-Syn Toxicity
a-Syn inclusions are a hallmark of toxicity in the yeast model and
are associated with lipids and neutral lipid droplets in yeast and
mammalian cells (Cole et al., 2002; Outeiro and Lindquist, 2003).
Pah1 controls the formation of cytosolic lipid droplets by cata-
lyzing the biosynthesis of DAG, and cells with abrogated Pah1
activity have fewer droplets than control cells (Adeyo et al.,
2011). To determine whether modulation of Pah1 affects a-Syn
inclusions, we first established that a-Syn binds lipids in our
model by demonstrating co-localization of YFP-tagged a-Syn
with Nile red-positive lipids (Figures S3C and S3D). Next, we
imaged YFP-tagged a-Syn in the Dnem1 strain and in the strain
expressing pah1–7A, a mutant with higher than wild-type activity
(Choi et al., 2011; O’Hara et al., 2006). We found that there were
significantly fewer cells with large a-Syn inclusions in the Dnem1
strain and significantly more in the pah1–7A strain relative to the
control strain (Figures 3C, 3D, and S3E). There were fewer inclu-
sions in the Dpah1 strain and in the strain in which PAH1 was re-
placed with the catalytically inactive mutant pah1-D398E than in
the control strain (Figures S3F and S3G) (Han et al., 2007).314 Cell Systems 9, 309–320, September 25, 2019Despitemodulation of toxicity by deletion ofNEM1 or expression
of pah1–7A, we observed co-localization of a-Syn with Nile red-
positive lipids (Figures S3C and S3D), and therewere fewer lipids
in Dnem1 cells and more lipids in pah1–7A a-Syn-expressing
cells than in wild-type cells that expressed a-Syn (Figure S3H).
In summary, these data show that a-Syn inclusion formation de-
pends on activation of Pah1.
To confirm that the phosphorylation status of Pah1 has an
effect on toxicity, we assayed growth of the pah1–7A strain.
The growth of yeast perturbed by both a-Syn and pah1–7A
expression was significantly lower than expected based on
each perturbation alone (Figure 4A), indicating a synergistic
interaction between the 7A mutant of Pah1 and a-Syn expres-
sion (Figure 4B). The 7D/E phospho-mimic of Pah1 did not
decrease the number of cells with inclusions or rescue growth
relative to cells that expressed wild-type Pah1 (Figures S3G,
S3I, and S3J). A possible explanation is that this phospho-mimic
does not have the same effect as endogenous phosphorylation,
a phenomenon known to occur (Paleologou et al., 2008). Since
Dpah1 and pah1-D398E strains were more resilient than
expected to the toxic effects of a-Syn there appears to be an
alleviating interaction between these mutations and a-Syn
(Figure 4B). This analysis of PAH1 mutants further supported
our hypothesis that Pah1 deactivation promotes rescue.
Deactivation of Pah1 results in decreased DAG levels, but also
in accumulation of PA and, consequently, expression of genes
known to be associated with phospholipid biosynthesis (Fig-
ure 4C) (Henry et al., 2012; White et al., 1991). We hypothesized
that rescue resulted from upregulation PA rather than a decrease
in the levels of DAG. We tested this possibility by growing
a-Syn-expressing yeast cells in inositol, which decreases
production of PA and thus inhibits phospholipid gene expres-
sion. If this pathway was the rescue mechanism, we would
expect enhanced toxicity in the presence of inositol, but we
found that inositol treatment did not enhance toxicity (Figure 4D),
Figure 4. Pah1 Activity in the DAG Branch of Lipid Metabolism Regulates a-Syn Toxicity in Yeast and Mammalian Cells
(A) Biomass of PAH1mutant-expressing yeast strains grownwith or without 1 nM estradiol to induce a-Syn expression weremonitored over 24 h. Light scattering
(620 nm) measurements were baselined on a well-by-well basis, summed, and divided bymean replicate intensity to obtain normalized biomass values (one-way
ANOVA adjusted for multiple comparisons, n = 4, alpha = 0.05).
(legend continued on next page)
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suggesting that the reduction in DAG biosynthesis rather than
accumulation of PA is relevant to the resistance of cells to
a-Syn-mediated toxicity.
Chemical Inhibition of Pah1 Activity Suppresses a-Syn
Toxicity in Yeast and Mammalian Cells
To determine whether chemical inhibition of Pah1 would protect
cells from a-Syn-induced toxicity, we treated a-Syn-expressing
yeast cells with the well-characterized Pah1 inhibitor propranolol
(Morlock et al., 1991). By monitoring biomass over 24 h, we
found that 2 mM propranolol significantly suppressed toxicity
in a Pah1-dependent manner (Figure 4E). This result further sup-
ports our conclusion that Pah1 activity promotes a-Syn toxicity
through the conversion of PA to DAG.
To determine whether lipins (LPIN1/2/3), the mammalian ho-
mologs of PAH1, modulate a-Syn toxicity in neuronal cells, we
treated mouse neuroblastoma N2A cells with fibrils pre-formed
from recombinant a-Syn in the presence and absence of pro-
pranolol and assayed for cell viability. We chose this model of
a-Syn toxicity because it better recapitulates PD hallmarks
such as accumulation of intracellular a-Syn inclusions and
neuronal toxicity than do models based on the intracellular
neuronal expression of a-Syn (Gerez et al., 2019; Luk et al.,
2009, 2012; Theillet et al., 2016). Administration of a-Syn fibrils
to N2A cells induced toxicity in a dose-dependent manner
(one-way ANOVA, p < 0.0001). At the highest dose of adminis-
tered a-Syn fibrils, cell viability was significantly increased by
treatment with 10 mMpropranolol (Figure 4F). In order to charac-
terize the effects of propranolol, we conducted a shotgun
phosphoproteomic analysis of a-Syn-expressing yeast cells
with and without propranolol treatment. We found that the
Pah1 network was affected by propranolol treatment, although
various other phosphoproteins unrelated to Pah1 were also
regulated (Figure S4A; Table S15). Finally, we silenced all three
LPIN genes in HEK293 cells treated with a-Syn fibrils (Fig-
ure S4B). Treatment with a-Syn fibrils alone or silencing of
LPIN genes alone both decreased viability of HEK293 cells; how-
ever, toxicity of a-Syn fibrils was decreased in cells in which all
three LPIN genes had been silenced compared to control cells
(Figure 4G). Overall, these results confirm our findings in yeast
and indicate that inhibition of lipin activity or silencing of LPIN
genes suppresses toxicity of a-Syn fibrils in mammalian cells.
DISCUSSION
a-Syn plays a crucial role in Parkinson’s disease (Polymeropou-
los et al., 1997; Singleton et al., 2003), but the mechanisms that
underlie this toxicity have remained cryptic making development(B) Observed biomass of strains expressing a-Syn and a Pah1 mutant (biomass
perturbation alone (biomass[a-Syn]*biomass[pah1mutant]). Biomass data from (A
(C) Schematic depicting possible downstream effects of phosphorylated Pah1 w
(D and E) Normalized biomass of indicated yeast strainsmeasured in the presence
ANOVA adjusted for multiple comparisons, alpha = 0.05).
(F) Viability of mouse N2A cells treated with a-Syn fibrils preformed from recombin
ANOVA adjusted for multiple comparisons, n = 4, alpha = 0.05).
(G) Viability of HEK293 cells transfected with a pool of siRNAs designed to inhib
alpha = 0.05).
Normalized biomass and cell viability values are displayed as mean ± standard d
316 Cell Systems 9, 309–320, September 25, 2019of effective therapies challenging. In this study, we simulta-
neously measured activation states of a multitude of pathways
and levels of proteins that are deregulated by expression of
a-Syn across a diverse set of known genetic modulators of
a-Syn toxicity. We applied multidimensional linear regression
analysis to identify biological processes that correlated with
the rescue from toxicity. Pah1 phosphorylation, which inhibits
its activity, was predicted to protect cells from the toxic effects
of a-Syn.
a-Syn expression in yeast results in lipid droplet (LD) accumu-
lation (Outeiro and Lindquist, 2003; Sere et al., 2010), and a-Syn
inclusions co-localize with LDs (Cole et al., 2002; Wang et al.,
2013). Our data show that Pah1 inhibition, which antagonizes
LD formation and lipid storage by halting DAG production
(Barbosa et al., 2015), ameliorates a-Syn-mediated toxicity and
results in the reduction of a-Syn inclusion formation, suggesting
tight links between a-Syn-mediated toxicity, lipid metabolism re-
sulting in DAG production, and LD formation.
In neurons, conditions such as hypoxia, lipid-loading, and
neurodegeneration induce formation of LDs (Pennetta and
Welte, 2018; Welte et al., 2005). In cultured human cells and pri-
mary neurons frommice, a-Syn binds to LDs and increases their
accumulation (Cole et al., 2002). Accumulation of a-Syn on LDs
reduces hydrolysis of triglycerides contained in the droplets in
mammalian cells (Cole et al., 2002). The interactions of a-Syn
with LDs may also provide a scaffold for a-Syn aggregation
and for the formation of Lewy bodies (Cole et al., 2002; Galvagn-
ion et al., 2015). Consistent with this hypothesis, Lewy bodies
contain accumulations of lipid vesicles (Shahmoradian et al.,
2019). Alternatively, the process of a-Syn amyloid formation
may be in competition with that of membrane binding. Interest-
ingly, LDs have been implicated in several motor neuron dis-
eases and accumulate upon neurodegeneration (Pennetta and
Welte, 2018).
Bioinformatic analyses revealed striking similarities between
the membrane-targeting motif of a-Syn and that of LD-binding
proteins of the perilipin (PLIN) family (Copic et al., 2018; Gime´-
nez-Andre´s et al., 2018). PLINs assemble on membranes
containing neutral lipids and promote packaging of lipids into
membrane-enclosed particles (Bulankina et al., 2009). PLINs
are also thought to physically protect LDs from lipase-induced
lipolysis (Granneman et al., 2009; Sztalryd and Brasaemle,
2017), and PLINs associate with DAG-rich ER membranes
(Skinner et al., 2009). Exogenous expression of mammalian
PLINs in yeast results in a phenotype similar to that of a-Syn
expression (Jacquier et al., 2013). We propose that a-Syn acts
as a PLIN to trigger the formation of LDs or to stabilize them
once they are formed by protecting them from the action of[a-Syn + pah1 mutant]) was compared to expected biomass based on each
) were used (two-way ANOVA adjusted for multiple comparisons, alpha = 0.05).
ith inhibitors highlighted in red.
or absence of (D) 75 mM inositol (n = 3) or (E) 2mMpropranolol (nR 3; one-way
ant protein and then treated for 36 hwith vehicle or 10 mMpropranolol (two-way
it expression of LPIN1-3 and treated with a-Syn fibrils (unpaired t test, n = 6,
eviation. ****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.05.
lipases. A number of previous findings support this hypothesis:
Expression of wild-type a-Syn causes accumulation of LDs,
whereas expression of mutant A30P a-Syn, which has low affin-
ity for membranes, does not cause LD accumulation in yeast
(Outeiro and Lindquist, 2003; Sere et al., 2010) and the A30P
mutant does not bind LDs in mammalian cells (Cole et al.,
2002). Moreover, removing the N-terminal region of a-Syn
responsible for membrane binding abolishes a-Syn toxicity and
inclusion formation in yeast (Soper et al., 2008; Vamvaca et al.,
2009). In addition, expression of PLINs recovers LD formation
in yeast cells with defects in lipid storage caused by deletion of
Pah1 (Jacquier et al., 2013), similar to our observation that
a-Syn expression is less toxic in Dpah1 or pah1-D398E yeast
mutants.
Consistent with our findings, a recent study showed that
inhibition of oleic acid biosynthesis in yeast, which is a few
biochemical steps upstream of Pah1, rescues cells from
a-Syn-induced toxicity. Deletion of DGA1 and LRO1, which
encode enzymes that convert DAG to TAG, showed that DAG
accumulation enhances toxicity of a-Syn possibly by increasing
DAG and oleic acid levels in the ER (Fanning et al., 2019). In
contrast, decreased DAG levels resulting from deletion of
TGL3/4 and growth in choline rescue yeast from toxicity (Fan-
ning et al., 2019). Although a role for phospholipid biosynthesis
downstream of Pah1 cannot be completely ruled out, our data
and data from Fanning et al. suggest that high DAG levels are
critical for a-Syn-mediated toxicity. Since yeast cells grow nor-
mally when DAG accumulates in the ER [e.g., when DGK1 is
deleted (Adeyo et al., 2011; Fanning et al., 2019; Han et al.,
2008)], it is possible that DAG accumulation is only toxic in
the presence of a-Syn. We speculate that a-Syn, like PLIN fam-
ily members (Bulankina et al., 2009; Copic et al., 2018; Granne-
man et al., 2009; Jacquier et al., 2013; Skinner et al., 2009), is
recruited to membranes with high DAG content altering mem-
brane properties and functions such as trafficking. It remains
to be determined if inactivation of Pah1, and the resulting
decrease in DAG levels, rescues yeast cells from a-Syn-medi-
ated toxicity primarily because it prevents excessive lipid
storage in LDs or because it prevents accumulation of DAG
in the ER and subsequent recruitment of a-Syn. Contrasting
findings have been reported regarding the toxicity of a-Syn in
yeast that cannot form LDs (Fanning et al., 2019; Sere et al.,
2010), and the localization of a-Syn in the absence of LDs in
yeast remains to be shown.
Data from mammalian models of a-Syn toxicity and human
cohorts suggest that some of the mechanisms that drive toxicity
of a-Syn in yeast are conserved in higher organisms and may be
relevant to PD. Our mammalian cell toxicity model is based on
internalization of pre-formed a-Syn amyloid fibrils, whereas our
yeast model is based on a-Syn expression. Therefore, the
intracellular conformational states of a-Syn may differ in the
two models. Despite this, inhibition of LPIN1/2/3 with proprano-
lol in neuronal cells and silencing of LPIN genes in human cells
treated with a-Syn fibrils both reduced a-Syn toxicity. Consistent
with these results, silencing of all LPIN genes reduced a-Syn
toxicity in rat cortical neurons, and DAG accumulation was
detected in a PD mouse model and in neurons with an a-Syn
triplication (Fanning et al., 2019). In support of our proposed
mechanism and its relevance to PD, the gene coding forDGKQ,which catalyzes the conversion of DAG to PA, the reverse
of the reaction catalyzed by Pah1 and LPINs, is associated with
an increased risk for PD (Nalls et al., 2014).
A recent study showed that B2AR is a regulator of a-Syn
expression through histone acetylation of its promoter and en-
hancers and that agonists of B2AR are protective in Parkinson
disease models (Mittal et al., 2017). In this same study, propran-
olol, an FDA-approved beta-adrenergic receptor antagonist,
was shown to increase a-Syn expression and to be associated
with an increased risk of PD. Here we demonstrated that pro-
pranolol suppressed toxicity due to a-Syn expression in yeast
and a-Syn fibril-treated neuroblastoma cells. Yeast cells used
in our screen lack B2AR and a-Syn was not expressed from
the endogenous promoter; therefore, in our model the protective
effects of propranolol prevailed. Similarly, N2A cells, the
neuronal model we used, do not express detectable levels of
B2AR (Hornburg et al., 2014), and toxicity was induced by exog-
enous pre-formed fibrils. This could explain why the protective
effects of propranolol were not previously observed, but addi-
tional work will be necessary to definitively explain these find-
ings. Given the increased risk of PD associated with propranolol
use and the potential off-target effects of the drug, we do not
support its testing as a PD therapy; however, more selective
LPIN or CTDNEP1 (the latter is the human ortholog of yeast
NEM1) inhibitors may hold promise for treatment of PD.
Our rapid and information-rich sentinel screening approach
simultaneously measures several hundred validated biological
markers, each representative of activation of the corresponding
pathway or module. This screen can be tailored to include
perturbation-specificmarkers aswe did here for a-Syn. Although
we focused here on Pah1, our screen predicted that modulation
of other pathways leads to rescue from a-Syn-induced toxicity.
One of these pathways involves Ero1, a marker for ER protein
folding, a process previously implicated in a-Syn toxicity in yeast
and in MPP+ Parkinson models (Lehtonen et al., 2016). Simulta-
neous perturbation of multiple pathways identified in our screen
may also lead to stronger rescue effects. Based on our partial
regression plots, alterations of the phosphorylation status of
Osh1 and Num1 are promising targets to combine with deactiva-
tion of Pah1. Intriguingly, the oxysterol-binding proteins Osh2
and Osh3 were previously discovered as genetic modulators of
a-Syn toxicity (Yeger-Lotem et al., 2009). Num1, a protein
involved in the mitochondria-ER-cortex-anchor (Lackner et al.,
2013), may provide another link between a-Syn and Pah1 at
the ER. We suggest testing of these candidates in future studies
aimed at assessing combinatorial effects on rescue.
The network analysis of paths linking genetic modulators to
Pah1 suggests mechanistic hypotheses regarding the roles of
previously reported toxicity modifiers. For example, altering
vesicle trafficking, and its modulators, may influence Pah1
through Nup84, a genetic interactor of the Nem1-Spo7 complex
(Siniossoglou et al., 1998). Similarly, the path from Ykt6 through
the Sec1-Sso1-Sso2-Sec22 network to Pkc1 may link auto-
phagy to Pah1 and a-Syn rescue and may explain previous re-
ports that these processes moderate a-Syn toxicity (Bas et al.,
2018; Nair et al., 2011; Reggiori and Klionsky, 2013; Sakaki
et al., 2008). Thus, the Pah1 network analysis provides context
for the top candidate from our screen and is a source of testable
hypotheses on interventions that could decrease a-Syn-inducedCell Systems 9, 309–320, September 25, 2019 317
toxicity. In summary, relating pathway activation data to
quantitative growth assays, as we did here through linear regres-
sion analyses, allows connection of modulators to their effectors
and enables formulation of testable mechanistic hypotheses.
Acquiring network fingerprints across a variety of conditions
may also provide ideal perturbative datasets for network recon-
struction or reverse engineering and for uncovering regulatory
links among pathways.
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Antibodies
Anti-Alpha-synuclein, mouse monoclonal [LB 509] Abcam Cat#ab27766; RRID:AB_727020
Bacterial Strains
E.coli: 10-beta Competent E. coli (High Efficiency) New England Biolabs Cat#C3019I
Chemicals, Peptides, and Recombinant Proteins
TCEP (tris(2-carboxyethyl)phosphine hydrochloride) Pierce Cat#20490; CAS#51805-45-9
Iodoacetamide Sigma-Aldrich Cat#I1149 ; CAS#144-48-9
Ammonium bicarbonate Sigma-Aldrich Cat#09830; CAS#1066-33-7
Urea Sigma-Aldrich Cat#U5128; CAS#57-13-6
Formic acid 98-100% AppliChem Cat#A38580500
Acetonitrile (HPLC) Fisher Chemical Cat#A998; CAS#75-05-8
Trifluoroacetic acid (HPLC) Sigma-Aldrich Cat#302031; CAS#76-05-1
Lysyl endopeptidase Wako Pure Chemical Industries Cat#125-05061
Trypsin: sequencing-grade modified trypsin Promega Cat#V5111
Titansphere Phos-TiO beads GL Sciences Cat#GL-5010-21315
Reprosil-Pur 120 C18-AQ, 3 mm 15 % C endc. Dr. Maisch GmbH Cat#r13.aq
Reprosil-Pur 120 C18-AQ, 1.9 mm 15 % C endc. Dr. Maisch GmbH Cat#r119.aq
b-Estradiol Sigma-Aldrich Cat#E8875; CAS#50-28-2
G418 Matthias Peter Lab CAS#108321-42-2
NotI-HF New England BioLabs Cat#R3189S
XmaI New England BioLabs Cat#R0180S
Propranolol hydrochloride Sigma-Aldrich Cat#P0884; CAS#318-98-9
myo-Inositol Karsten Weis Lab CAS#87-89-8
Nile Red Thermo Fisher Scientific Cat#N1142; Cas#7385-67-3
Propidium iodide Sigma-Aldrich Cat#P4170; CAS#25535-16-4
Recombinant a-Syn (Gerez et al., 2019) N/A
SuperScript II reverse transcriptase Invitrogen Cat#18064014
RNaseOUT recombinant ribonuclease inhibitor Invitrogen Cat#10777019
Random primers Biodynamics Cat#B070-40
Critical Commercial Assays
BCA Pierce Cat#23225
CellTiter 96 Non-Radioactive Cell Proliferation
Assay (MTT)
Promega Cat#G4000
iRT Kit Biognosys AG Cat#Ki-3002-1
RNeasy Mini Kit Qiagen Cat#74104
Deposited Data
Shotgun Data PeptideAtlas: PASS01407 http://www.peptideatlas.org/PASS/PASS01407
PRM data PeptideAtlas: PASS01409 http://www.peptideatlas.org/PASS/PASS01409
Experimental Models: Cell Lines
Human embryonic kidney 293 (HEK293) ATCC CRL-1573
Mouse neuroblastoma (N2A) ATCC CCL-131
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Experimental Models: Organisms/Strains
S. cerevisiae: IntTox/a-Syn: W303 MATa, can1–100,
his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1,
GAL1- aSyn-YFP::HIS3 and GAL1-aSyn-YFP::TRP1
Pavan Auluck; Susan Lindquist
lab; (Cooper et al., 2006)
N/A
S. cerevisiae: Vector/Empty vector: W303 MATa,
can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1,
ade2-1, GAL1-empty::HIS3 and GAL1-empty::TRP1
Pavan Auluck; Susan Lindquist
lab; (Cooper et al., 2006)
N/A
S. cerevisiae: GFP: W303 MATa, can1-100,





S. cerevisiae: TDP-43-GFP: W303 MATa, can1-100,





S. cerevisiae: FUS: W303 MATa, can1-100,





S. cerevisiae: aSyn Dnem1: W303 MATa, can1-100,
his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1,
GAL1- aSyn-YFP::HIS3 and GAL1-aSyn-YFP::TRP1,
nem1::Kan
this study N/A
S. cerevisiae: Vector Dnem1: W303 MATa, can1-100,
his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1,
GAL1-empty::HIS3 and GAL1-empty::TRP1, nem1::Kan
this study N/A
S. cerevisiae: GFP Dnem1: W303 MATa, can1-100,
his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1,
GAL1-GFP::HIS3 and GAL1-GFP::TRP1, nem1::Kan
this study N/A
S. cerevisiae: TDP-43-GFP Dnem1: W303 MATa,
can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1,
ade2-1, GAL1-TDP-43::HIS3 and GAL1-TDP-
43::TRP1, nem1::Kan
this study N/A
S. cerevisiae: FUS Dnem1: W303 MATa, can1-100,
his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1,
GAL1-FUS::HIS3, nem1::Kan
this study N/A
S. cerevisiae: aSyn Dpah1: W303 MATa, can1-100,
his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1,
GAL1- aSyn-YFP::HIS3 and GAL1-aSyn-YFP::
TRP1, pah1::Kan
this study N/A
S. cerevisiae: aSyn pah1-7A: W303 MATa, can1-100,
his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1,
GAL1- aSyn-YFP::HIS3 and GAL1-aSyn-YFP::
TRP1, pah1::Kan, pah1-7A::URA3
this study N/A
S. cerevisiae: aSyn pah1-7D/E: W303 MATa,
can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1,
ade2-1, GAL1- aSyn-YFP::HIS3 and GAL1-aSyn-
YFP::TRP1, pah1::Kan, pah1-7D/E::URA3
this study N/A
S. cerevisiae: aSyn pah1-D398E: W303 MATa,
can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1,
ade2-1, GAL1- aSyn-YFP::HIS3 and GAL1-aSyn-
YFP::TRP1, pah1::Kan, pah1-D398E::URA3
this study N/A
S. cerevisiae: Estradiol-inducible a-Syn: W303 can1-





S. cerevisiae: Estradiol-inducible a-Syn Dpah1:
W303 can1-100, his3-11,15, leu2-3,112, trp1-1,
ura3-1, ade2-1, a-Syn::LEU2 and GAL4-ER-
VP16::TRP1, pah1::Kan
this study N/A
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S. cerevisiae: Estradiol-inducible a-Syn pah1-
WT: W303 can1-100, his3-11,15, leu2-3,112,
trp1-1, ura3-1, ade2-1, a-Syn::LEU2 and GAL4-
ER-VP16::TRP1, pah1::Kan, pah1-WT::URA3
this study N/A
S. cerevisiae: Estradiol-inducible a-Syn pah1-7A:
W303 can1-100, his3-11,15, leu2-3,112, trp1-1,
ura3-1, ade2-1, a-Syn::LEU2 and GAL4-ER-VP16::
TRP1, pah1::Kan, pah1-7A::URA3
this study N/A
S. cerevisiae: Estradiol-inducible a-Syn pah1-7D/E:
W303 can1-100, his3-11,15, leu2-3,112, trp1-1,
ura3-1, ade2-1, a-Syn::LEU2 and GAL4-ER-VP16::
TRP1, pah1::Kan, pah1-7D/E::URA3
this study N/A
S. cerevisiae: Estradiol-inducible a-Syn pah1-
D398E: W303 can1-100, his3-11,15, leu2-3,112,




See Table S16 this study N/A
Recombinant DNA
a-Syn modulator plasmids: each gene in Table S5
in pBY011; CEN, URA3, AmpR
(Cooper et al., 2006) N/A
pFA6a-KanMX6 (Longtine et al., 1998) N/A
pGH315, pah1 Inserted into pRS415 (Choi et al., 2011) N/A
pGH315(7A), pah1 (S110A/S114A/S168A/S602A/
T723A/S744A/S748A) inserted into pRS415
(Choi et al., 2011) N/A
pGH315(7D/E), pah1 (S110D/S114D/S168D/S602D/
T723E/S744D/S748D) inserted into pRS415
(Hsieh et al., 2016) N/A
pGH312(D398E), HA-tagged pah1 (D398E) (Han et al., 2007) N/A
pRS306, yeast integrative vector with URA3 marker Matthias Peter Lab ATCC 77141
pMS1, pah1-WT inserted into pRS306 this study N/A
pMS2, pah1-7A inserted into pRS306 this study N/A
pMS3, pah1-D398E inserted into pRS306 this study N/A
pMS4, pah1-7D/E inserted into pRS306 this study N/A
Software and Algorithms
Skyline-daily v 2.0.9.4899 Michael MacCoss lab https://skyline.ms/project/home/software/
Skyline/begin.view
R v. 3.1.1 & 3.5.1 The R Project for Statistical
Computing
https://www.r-project.org/
MSstats v. 0.99 (Choi et al., 2014) http://bioconductor.org/packages/release/
bioc/html/MSstats.html
Proteome discoverer v. 1.4 & 2.0 Thermo Fisher Scientific https://www.thermofisher.com/ca/en/
home.html
Xcalibur v. 3.1 Thermo Fisher Scientific https://www.thermofisher.com/ca/en/
home.html
Progenesis QI Nonlinear dynamics http://www.nonlinear.com/progenesis/
qi-for-proteomics/
SafeQuant v. 2.01 (Glatter et al., 2012) https://cran.r-project.org/web/packages/
SafeQuant/index.html
FunSpec (Robinson et al., 2002) http://funspec.med.utoronto.ca/
Saccharomyces Genome Database (SGD) (Cherry et al., 2012) https://www.yeastgenome.org/
ImageJ v 1.47d Wayne Rasband, National
Institutes of Health, USA
https://imagej.nih.gov/ij/
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CellProfiler v. 3.1.8 CellProfiler cell image analysis
software
https://cellprofiler.org/
STRING v. 10.5 & 11.0 (Szklarczyk et al., 2019) https://string-db.org/
c060 v. 0.2-4 (Sill et al., 2014) https://cran.r-project.org/web/packages/
c060/index.html
igraph v. 1.2.4 (Csardi and Nepusz, 2006) https://cran.r-project.org/web/packages/
igraph/index.html
network v. 1.15 (Butts, 2008) https://cran.r-project.org/web/packages/
network/index.html
ggnetwork v. 0.5.1 (Briatte, 2016) https://cran.r-project.org/web/packages/
ggnetwork/index.html
GraphPad Prism v 7.0c GraphPad https://www.graphpad.com/
Other
FastPrep-24 5G MP biomedicals https://ch.mpbio.com/
BioLector m2p labs https://www.m2p-labs.com/bioreactors/
products/biolector/
FACSCalibur flow cytometer BD Biosciences https://www.bd.com/
DM6000B microscope Leica microsystems https://www.leica-microsystems.com/
Eclipse Ti microscope Nikon https://www.microscope.healthcare.nikon.com
Q-Exactive Plus mass spectrometer Thermo Fisher Scientific https://www.thermofisher.com/ca/en/home.htmlLEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Paola
Picotti (picotti@imsb.biol.ethz.ch).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Saccharomyces cerevisiae
Yeast W303 cells were grown at 30C in synthetic defined (SD) medium picked from a single colony and sampled at 6 h post-induc-
tion of a-Syn from log-phase growth, except where specified in Method Details.
Mammalian Cell Lines
Human embryonic kidney 293 (HEK293) cells (sex: female) were grown in Dulbecco’s Modified Eagle Media (DMEM) with 10% fetal
bovine serum (FBS) and 1% Penicillin-Streptomycin (Pen-Strep) at 37C and 5% CO2. Mouse neuroblastoma (N2A) cells (sex: male)
weremaintained in DMEMwith 10%FBS and 1%Pen-Strep, and grown in DMEMwith 2%FBS and 1%Pen-Strepwhen treatedwith
a-Syn pre-formed fibrils. Cell lines were passaged up to 5 times and routinely tested negative for mycoplasma contamination.
METHOD DETAILS
Yeast Strain Phenotyping
Cells were grown overnight at 30 C in synthetic defined (SD) liquid medium containing 2% glucose with appropriate dropout and
then diluted and grown overnight in 2% raffinose dropout medium. To induce a-Syn expression, cells were diluted to 0.3 OD600 in
2% galactose SDmedium. Live cells were imaged on a Leica DM6000Bmicroscope with a 60X objective in the GFP channel. Images
were processed in ImageJ.
For growth assessment, 100 ml of a 0.15 OD600 culture in 2% galactose SD medium was transferred to a 96-well plate. Biomass
(measured by monitoring 620 nm) was recorded for 24 h by a BioLector microbioreactor. The system was set to a temperature of 30
C, humidity of 85%, 20.95%O2, and 800 rpm. The baseline was established on a well-by-well basis according to the average signal
of the six time points with the lowest standard deviation across the dataset. Errors are the standard deviations of three biological
replicates.
For viability measurements, 100 ml of sample was diluted to 1 ml with PBS and 1 ml of 2 mg/ml propidium iodide was added. Sam-
ples were incubated on ice for 10 min in the dark. Cells were pelleted, and the supernatant was discarded. To the sample was added
1 mL of PBS, and 10,000 cells were analyzed by flow cytometry (emission at 617 nm, excitation at 535 nm).e4 Cell Systems 9, 309–320.e1–e8, September 25, 2019
Shotgun Proteomic Analysis
Shotgun proteomic measurements and label-free quantification were carried out on the yeast strain with two copies of a-Syn (IntTox
strain) and an empty vector-containing control at 6 h post induction. This time point was selected because a-Syn-YFP inclusions
were visible, growth curves of vector- and a-Syn-expressing cells had begun to separate, and death rates were negligible. Cell pellets
were mechanically disrupted by bead beating in a FastPrep-24 5G device, protein lysates were digested with trypsin and Lys-C, and
peptides were purified and phosphopeptides were isolated using Titansphere Phos-TiO beads as previously described (Soste et al.,
2014). Peptides were chromatographically eluted from a 50-cm heated column (60 C) packed with 1.9-mm C18 beads using a 2-h
gradient of 5% to 35% acetonitrile. Peptides were analyzed on a Q-Exactive Plus mass spectrometer operated in DDA mode. Pro-
teins and phosphopeptides were identified by searching the SGDProtein Database with a peptide false discovery rate of < 0.01 using
Proteome Discoverer software. MS1 peak identification by Progenesis and quantification and plotting by Safequant (Glatter et al.,
2012) were used to find significantly regulated features (fold change R 2, q % 0.01). Functional enrichment analysis was carried
out using FunSpec (Robinson et al., 2002). GO (Ashburner et al., 2000) and MIPS (Mewes et al., 2002) categories were searched.
For enriched categories, a significance cutoff of p-value% 0.05 with Bonferroni correction was used.
Quantification of Modulator Rescue
For genetic modulation of toxicity, a-Syn-expressing and empty vector-expressing strains were transformed with an extrachromo-
somal plasmid for galactose-inducible expression of modulators (Cooper et al., 2006). a-Syn yeast strains expressing the different
modulators were cultured in four batches. For the first three batches (13 modulators), cells were grown as described above in three
biological replicates. The additional 20 modulators were tested in singlicate as a fourth batch. For induction of a-Syn and modulator
expression, cells were diluted to 0.15 OD600 in 2% galactose SDmedium. Growth was assessed in technical duplicates or triplicates
as described above in amicrobioreactor. Biomass values were used to quantify rescue. Baselines were established on awell-by-well
basis based on averaged signals of the first six time points, then all biomass values over 24 h were summed. The specific rescue by
each modulator was calculated by dividing the ratio of the biomass of strain expressing a-Syn plus modulator to strain expressing
a-Syn alone by the ratio of the biomass of strain expressing vector plus modulator to vector alone. The mean value of replicates was
used for modulators tested in triplicate.
Addition of a-Syn-Specific Markers to the Sentinel Assay
In addition to monitoring generic yeast cellular process (phospho)protein markers (Soste et al., 2014), a-Syn-specific markers were
selected from the significantly regulated (phospho)proteins identified in the shotgun proteomic analysis (fold changeR 2, q% 0.01).
Proteotypicity was verified, and these targets were measured by PRM targeted mass spectrometry in order to confirm the label-free
quantification.Markers were prioritized if the amplitude of their response in PRMand shotgun data was high indicating a greater likeli-
hood for detection in a multiplexed PRM assay and potentially large fold change induced by a-Syn. Phosphopeptide targets were
also preferred if their respective protein occurred multiple times in the candidate list, potentially suggesting multiple PTM changes
caused by a-Syn. (Phospho)proteins were also prioritized based on their functional characterization and prior knowledge of how this
may relate to known a-Syn biology ormay lead to novel findings in the case of uncharacterized candidates. Finally, (phospho)proteins
with a human homolog were favored to facilitate future testing. Using these criteria, 29 proteins and 65 phosphopeptides were added
as a-Syn-specific sentinels. Assayswere also generated for S87 phosphorylated a-Syn (added to phosphorylation assay), K12-, K21-
, and K96-ubiquitinated a-Syn, the propeptide (YMR297Wpro), and the mature (YMR297Wmat) forms of Cpy1 (all added to protein
assay) based on literature evidence of involvement in toxicity. The final proteomic assay attempted to monitor a total of 376 pathway
sentinels (188 proteins and 188 phosphopeptides), 26% of which were a-Syn-specific.
Pathway Monitoring across a-Syn Modulators
Quantification of sentinels was done using targeted proteomics as previously described (Soste et al., 2014) except for two differ-
ences: the addition of a-Syn-specific sentinels and adaptation of the assay from selected reaction monitoring to PRM mass spec-
trometry. The assay was implemented on a Q-Exactive Plusmass spectrometer operated in PRMmode. Peptides were eluted from a
20-cm column packed with 3-mmC18 beads using a 5% to 35% acetonitrile gradient over 40 min. iRT peptides were used for sched-
uling 3-min windows for detecting each target. Raw PRM traces were manually evaluated in Skyline and 3-10 transitions per target
and per analysis batch were exported for normalization and quantification by MSStats (Choi et al., 2014). Phosphopeptides and pro-
teins not detected in at least one sample were removed. If a peptide was determined to be detected in all samples but one ormore low
intensity transitions in some samples had a peak area less than an average noise value (6 transition peak areas where no peptides are
detected) then the average noise value, across all batches, was input for the quantification. For protein quantification, noise valuewas
set to a peak area of 2080 and for phosphopeptide quantification, the noise value was set to 3466. In total, 0.0018 of the quantified
values were noise values. In total 269/376 sentinels were quantified across 33 genetic modulators in four separate batches. One
empty vector, without a-Syn, and one unmodulated a-Syn sample were analyzed in each batch.
Data Processing and Modeling of Rescue
Using the quantified results from MSStats, a phosphopeptide matrix and a protein matrix were created that contained log2 fold
change values relative to the vector sample for 103 phosphosites and 166 proteins across the 37 samples. We corrected for batch
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the mean for robustness against outliers. Protein and phosphopeptide features were hierarchically clustered in rows according to
batch-corrected fold change values relative to the vector samples and using Euclidean distance and the complete linkage method.
Wemodeled the rescue effect Y as a function of the activities of all sentinels Sj (i.e., the pathway marker abundance values) across




ajSij + ei (Equation 1)
Here, Yi is the growth effect of modulator i relative to the wild-type control, and Sij is the activity (abundance) of sentinel j for the i
th
modulator. The fitting parameter aj is the partial effect of sentinel j on the rescue, and a is the intercept. Since all sentinels aremodeled
together the effect of the jth sentinel is estimated as if all other sentinels were held constant. The error term in the model is denoted by
ei. In order to retrieve themost relevant sentinels, we aimed to obtain a sparsemodel using lassowith stability selection (Meinshausen
and B€uhlmann, 2010). Stability selection is a general approach that combines (regularized) regression models with resampling and
aims to find stable sentinels showing strong association with the rescue. Specifically, we used the function ‘stabpath’ from the R
package ‘c060’ (Sill et al., 2014) with default parameters. The stability selection algorithm was applied twice: once for the phospho-
peptides and once for the proteins. We used the average log2 rescue as a response variable. The input variables were the batch-cor-
rected log2 fold changes of all 103 phosphopeptides and the batch-corrected log2 fold changes of all 166 proteins. The protein
YMR297W (Cpy1) is a degradation-based sentinel; an increase in propeptide abundance relative to total protein abundance reports
the known a-Syn induced block in ER to Golgi vesicle trafficking. The two features YMR297Wpro and YMR297Wmat were therefore
counted as one protein sentinel and removed from the protein matrix so that the difference between their values could be considered
instead (ratio in the raw space). It was necessary to use regularization since the number of observations/samples (n = 37) is much
smaller than the number of variables (p = 103 and 166, respectively). Stable features were classified as sentinels with a maximal se-
lection probabilityR 0.6. In order to determine the sign of the effect (i.e., coefficient) of the stable features, we fit a linear model, one
for the phosphopeptides and one for the proteins, with the same response variable but with the fold changes of the stable features as
the sole input variables. As opposed to simple linear regression/correlation analysis, in multiple linear regression the coefficient of
each feature measures the effect of that feature on the output given that the values for all other features in the model are held con-
stant. Equivalently, it measures the unique effect of that feature on the output by removing the linear effects of all other features.When
two sentinels are correlated to each other (positively or negatively) the coefficients in the combined model may deviate substantially
from simple pairwise correlations between sentinels and responses.
Enrichment Analysis of Sentinels Oppositely Regulated between Enhancers and Suppressors
A cluster of 107 sentinels was observed to be oppositely regulated when comparing genetic enhancers and suppressors of toxicity.
These sentinelsmapped to 100 unique yeast proteins. Funspecwas used to test for functional classes enriched in this set of proteins.
Using Bonferroni correction and a p-value cutoff of 0.05, GO and MIPS categories were identified.
Network Analysis of a-Syn Genetic Modulators and Pah1 Regulators
The STRING network for Saccharomyces cerevisiae was filtered for high-confidence edges (interaction score above 0.9), and sub-
sequently the largest connected component was retained. This consisted of 4,084 nodes and 54,540 edges. The Saccharomyces
genome databasewas used to link systematic names (STRING identifiers) and standard names (Cherry et al., 2012). Of the 33 genetic
modulators, 25 were present in the largest component. Pah1 was also present in this component. For each of the 25modulators pre-
sent in the largest connected component we computed all shortest paths to each of the following upstream regulators of Pah1:
Nem1-Spo7 complex components (Nem1, Spo7), Cdc28, PKA complex components (Bcy1, Tpk1/2/3), casein kinase II complex
components (Cka1/2, Ckb1/2), Pho80-85 complex (Pho80, Pho85), and Pkc1. This procedure identified the shortest path (or paths)
from each modulator to all 14 regulators of Pah1 phosphorylation. We kept the shortest (of the shortest to all regulators) in order to
identify the closest of the 14 Pah1 regulator(s). Ties can arise at two stages: if more than one regulator is equally close to a given
geneticmodulator and if there aremultiple shortest paths leading to the same closest regulator. In the case of ties, we kept all shortest
paths for the subsequent analysis. The nodes included in the shortest (of the shortest) paths, together with Nem1, Pho80, and Pho85
(i.e., protein Pah1 regulators that are not the closest target of any of the 25modulators), were used to finally generate the subnetwork.
The closest regulator was annotated for each modulator. Eight modulators not found in the largest component were kept as isolated
nodes. Since the STRING network is undirected, we excluded Pah1 from the largest connected component when computing the
shortest paths because we assumed that Pah1 is the downstream endpoint of the regulators (i.e., to avoid artifacts, the discovered
shortest path was not permitted to go from a modulator through Pah1 to one of the regulators).
In order to annotate the correspondence between Pah1 phosphorylation fold change (FC) induced by a given modulator and the
network path distance of the same modulator to the closest Pah1 regulator, the absolute FC value was plotted against the length of
the shortest distance path. Infinite (Inf) indicates that themodulator was not connected to any Pah1 regulator in the network. To test if
modulators closer to Pah1 regulators had a greater average absolute FC, a one-tailed (two-sample) t-test was applied to the group of
modulators at shortest distance equal to 1 or 2 compared to those at 3, 4 or Inf.e6 Cell Systems 9, 309–320.e1–e8, September 25, 2019
In order to identify central nodes, we computed for each node of the subgraph its betweenness (i.e., the number of shortest paths







where sst is the total number of shortest paths from node s to node t and sstðvÞ is the number of those paths that pass through v. This
score was chosen as a measure of centrality because we previously computed the shortest paths in order to generate the
subnetwork.
Strain Construction and Growth Assessment
Deletions of NEM1 and PAH1 were done using standard procedures by targeting the KanMX cassette to each target gene (Longtine
et al., 1998). Colonies selected by growth in G418 were confirmed to have the correct gene deletion by PCR and sequencing. pah1-
WT, pah1–7A, pah1–7D/E, and pah1-D398E genes were amplified from plasmids that were a generous gift from George Carman and
Gil-Soo Han (Rutgers University) (Choi et al., 2011) and were integrated at the URA locus via the vector pRS306. Yeast transforma-
tions were done using standard procedures. Serial dilutions of 0.3 OD raffinose cultures of yeast strains were spotted onto glucose
and galactose plates and imaged 3 days after spotting in biological triplicate.
Live-Cell Microscopy
Fluorescence microscopy images were taken 6 h post induction in a 96-well plate mounted on the stage of a Nikon Eclipse Ti micro-
scope equippedwith a 100x oil objective. a-Synwas imaged in the YFP channel. Z stacks were acquired at 0.25-mm intervals, and the
resulting images were merged to maximum intensity projections in ImageJ. Cells with and without visible inclusions were counted
manually in ImageJ. At least 95 cells were counted in each of three fields of view, and the results were averaged and tested for sig-
nificance by one-way ANOVA adjusted for multiple comparisons. Imaging was conducted in at least biological triplicate, except for
a-Syn-expressing Dpah1, pah1-D398E, and pah1-7D/E, which were each evaluated once. For these latter strains, three or four
different fields of view were used for statistical testing. The a-Syn-expressing Dnem1 and a-Syn strains were stained with Nile red
using a final concentration of 0.5 mg/mL. After 5 min incubation at 30 C, cells were washed with PBS before live cell imaging.
Nile red staining was imaged in the RFP channel.
For assessment of co-localization and quantification of Nile red intensity, three regions of interest (ROI) from three fields of view per
biological replicate were used as input for a co-localization pipeline in CellProfiler. Nile red and YFP channels were measured across
the entire ROI with a threshold of 15% of maximum intensity and reported normalized covariance (Pearson r). To quantify lipid abun-
dance, objects were identified in images with a diameter range of 20-100 pixels. An average of 252 Nile red positive objects and 409
YFP-positive objects were found per biological replicate. Three biological replicates were assessed for a-Syn and a-Syn Dnem1
samples, and two biological replicates were tested for a-Syn pah1-7A. A module was added to the pipeline in order to measure
the Nile red intensity only within areas enclosed by Nile red-positive objects. The integrated intensity of the sum of pixel intensities
within an object (arbitrary units) was used for quantification. Pearson r and integrated intensity values were averaged across all ROIs
and images within each biological replicate of a given sample.
Quantification of a-Syn Abundance
a-Syn abundance in a-Syn-expressing Dnem1, pah1-WT, and pah1-7A yeast was assessed by western blot (anti-a-Syn, ab27766,
Abcam), and equal loading of total protein was confirmed by Ponceau staining.
Quantification of Pah1 Phosphorylation
Phosphopeptides were enriched from whole-cell lysates as described above. PRM was used to quantify 18 transitions from two
phosphopeptides mapping to three known Nem1-target phosphosites and 11 transitions from two phosphopeptides containing
two phosphosites not targeted by Nem1. Abundances were determined using MSStats and normalized by total ion chromatogram
and Pah1 protein abundancemeasured from protein lysates. Abundance levels were quantified by summed transition area relative to
mean sum transition areas in vector sample for each peptide across biological triplicates. Mean abundances for Nem1 target and
non-target phosphopeptides were compared between a-Syn and a-Syn Dnem1 by two-way ANOVA adjusted for multiple compar-
isons, n=6, alpha=0.05 in order to assess if Pah1 phosphorylation was significantly different at Nem1-target sites and at non-
target sites.
Pah1 Perturbation and Rescue Assessment
Suppression or enhancement of toxicity in PAH1 mutants and due to chemical treatments was assessed as described above for
modulator rescues. Normalized biomasses were calculated by dividing raw sum biomass values for each sample by the average
signal intensity for all samples per replicate in order to eliminate technical variation between replicates measured at different times.
Yeast with the estradiol transcriptional regulator integrated at the TRP locus and a-Syn under the control of an estradiol-regulated
promoter at the LEU locus were cultured in galactosemedia and induced to express a-Syn by growth inmedia containing 1 nM estra-
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was added to media in order to inhibit expression of genes involved in phospholipid biosynthesis. Propranolol was dissolved in water
and spiked into cultures at 2 mM; control samples were treated with water only. The concentration of 2 mM propranolol was previ-
ously used to inhibit Pah1 in yeast (Sasser et al., 2012). Shotgun proteomics for protein and phosphopeptide abundance changes in
propranolol treated a-Syn yeast versus untreated a-Syn yeast was conducted as described above except Proteome Discoverer v2.0
was used for label-free quantification. Samples were harvested for analysis 24 h post-estradiol induction of a-Syn. A fold-change
cutoff of 2 and a q value% 0.05 were used to identify regulated proteins and phosphopeptides. The corresponding proteins of regu-
lated phosphopeptides were input into STRING v11.0 in order to find clusters of interacting proteins. A confidence threshold of 0.9
interaction score was applied, disconnected nodes were omitted and K-means clustering was set to 10.
Analysis of Interactions between a-Syn Expression and PAH1 Mutants
We tested for interactions between the a-Syn perturbation and each PAH1 mutation. We defined the expected effect on growth as
the product of the biomass of the individual perturbations (biomass(a-Syn) * biomass(pah1-mutant)). This method has been used to
define a neutrality function that predicts the phenotype of two non-interacting mutations (Mani et al., 2008). We then compared the
actual observed phenotype of the double-perturbation (biomass(a-Syn + pah1-mutant) to determine if it was significantly different
than the expected phenotype.
Suppression of Toxicity by Propranolol in Mammalian Neuroblast Cells
N2A cells were incubated for 24 h with PBS or exogenous a-Syn fibrils (0.25 and 1 mM) produced from recombinant a-Syn as pre-
viously described (Gerez et al., 2019; Luk et al., 2012). Cells were treated with vehicle or 10 mM propranolol for 36 h, and cell viability
was assessed byMTT assay (Promega). Compared to the yeast experiment, a lower dose of propranolol was used onN2A cells since
yeast have a cell wall and N2A cells do not.
Suppression of Toxicity by Knockdown of Lipin Genes in Human Cells
HEK293 cells were transfected with a control siRNA (cat# D-001810-01-05, Dharmacon) or a pool of siRNAs targeting the PAH1
orthologs, lipin1, lipin2, and lipin3 (LPIN1a: cat# J-017427-09-0002, LPIN1b: cat# J-017427-11-0002, LPIN2a: cat# J-013458-09-
0002, LPIN2b: cat# J-013458-11-0002, LPIN3a: cat# J-032702-07-0002, LPIN3b: cat# J-032702-08-0002, all from Dharmacon).
After transfection, the cells were treated with exogenously produced a-Syn fibrils (1 mM). Viability was assessed by MTT assay.
The efficiency of siRNA-mediated knockdown of LPIN genes was assessed by RT-PCR. HEK293 cells were transfected with
siRNAs, and the mRNAs of each LPIN gene were amplified by non-saturating PCR. HSC70, an unrelated mRNA, was used as a
loading control. For RT-PCR, total RNA was isolated from the cells using RNeasy Mini Kit following manufacturer’s instructions.
For reverse transcription, 1 mg of RNA was incubated for 1 h at 37 C with SuperScript II reverse transcriptase in the presence of
RNaseOUT RNase inhibitor and random primers, followed by an inactivation step at 95 C for 5 min. The obtained complementary
DNA (cDNA) was used as template in a 28-cycle PCR performed with the following specific primers: human LPIN1 fwd: TGCTGGA
GAGCAGCAGAACTC; human LPIN1 rev: TAGGGTATGAGGCTGACTGAG; human LPIN2 fwd: CCTCTCCTCAGACCAGATCG;
human LPIN2 rev: GGAGAATCTGTCCCAAAGCA; human LPIN3 fwd: CACTCCACCCTCCACTCCTA; human LPIN3 rev: ACAGGTA
GATGGTGGCCTTG; human HSC70 fwd: GGAGGTGGCACTTTTGATGT and human HSC70: GTACGGAGGCGTCTTACAGC.
Amplified products were electrophoresed in a 1.5% agarose gel and stained with SYBR Green PCR.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical tests were performed using SafeQuant (v. 2.01), MSstats (v. 0.99), Proteome Discoverer (v. 2.0) and GraphPad Prism
(v. 7.0c). Methods of quantification and statistical analysis, including which test was used, the value and meaning of n, definition
of center and dispersion and precision measures are included in the figure legends andMethod Details section of the corresponding
experiment. Unless otherwise specified, n denotes the number of independent biological samples tested in the experiment. Data in
bar and box plots are represented as mean ± Standard Deviation (SD). Significance levels are defined in the figure and table legends.
No explicit methods were used to test whether the data met certain assumptions or to determine strategies for randomization, sam-
ple size estimation and inclusion or exclusion of any data. For the regression and network analyses, the statistical language R (v.
3.5.1) has been used. In particular, for the regression analysis (stability selection) the R package ‘c060’ (v. 0.2-4) was used, while
for the network analysis and the network visualization we have used the R packages ‘igraph’ (v. 1.2.4) (Csardi and Nepusz, 2006),
‘network’ (v. 1.15) (Butts, 2008) and ‘ggnetwork’ (v. 0.5.1) (Briatte, 2016). All the details of the methods, including thresholds, sample
size and number of variables/parameters, can be found in the Method Details and the figure legends.
DATA AND CODE AVAILABILITY
The accession number for the proteomics shotgun data reported in this paper is PeptideAtlas: PASS01407 (http://www.peptideatlas.
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